TrialBMC infectious diseases2017

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Evan B Cunningham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.